Great Lakes Clinical Trials is proud to share clinical trial results from a study conducted by our COVID research specialists in conjunction with our hospital partners including Swedish Hospital, Weiss Memorial Hospital and West Suburban Medical Center.
This clinical trial (called “EMPACTA”), was sponsored by Roche/Genentech and showed that Actemra/RoActemra reduced the likelihood of needing mechanical ventilation in hospitalized patients with COVID-19 associated pneumonia.
“Importantly this was first global phase III COVID trial with a focus on enrolling largely underserved and minority patients,” commented Steve Satek, President of Great Lakes Clinical Trials. Approximately 85% of the 389 patients were from minority racial and ethnic groups. The majority of patients were Hispanic, with significant representation of Native American and Black populations.
We are proud to work so closely with our hospital partners on our COVID studies, and provide access to global clinical trials within the north side communities of Chicago. Besides Great Lakes Clinical Trials, this study was conducted at 69 research center throughout the United States, South Africa, Kenya, Brazil, Mexico and Peru.
To view the current COVID-related research studies being conducted at Great Lakes Clinical Trials, including our upcoming vaccine programs, please click HERE.
To view the original press release from Roche/Genentech , click on the button below.